Last reviewed · How we verify
recombinant human C1 inhibitor
recombinant human C1 inhibitor is a Complement system regulator Small molecule drug developed by Pharming Technologies B.V.. It is currently in Phase 3 development for Hereditary angioedema. Also known as: "rhC1INH", Ruconest, conestat alfa, rhC1INH.
Recombinant human C1 inhibitor works by replacing a deficient or dysfunctional C1 inhibitor protein to regulate the complement system and prevent excessive inflammation.
Recombinant human C1 inhibitor works by replacing a deficient or dysfunctional C1 inhibitor protein to regulate the complement system and prevent excessive inflammation. Used for Hereditary angioedema.
At a glance
| Generic name | recombinant human C1 inhibitor |
|---|---|
| Also known as | "rhC1INH", Ruconest, conestat alfa, rhC1INH, Conestat alfa |
| Sponsor | Pharming Technologies B.V. |
| Drug class | Complement system regulator |
| Target | C1 inhibitor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The recombinant human C1 inhibitor protein is a naturally occurring regulator of the complement system, which plays a crucial role in the body's immune response. By replacing a deficient or dysfunctional C1 inhibitor protein, this drug helps to prevent excessive inflammation and tissue damage. This can be particularly beneficial for individuals with hereditary angioedema, a condition characterized by recurring episodes of severe swelling.
Approved indications
- Hereditary angioedema
Common side effects
- Injection site reactions
- Headache
- Nausea
- Fatigue
Key clinical trials
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (PHASE1, PHASE2)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection (PHASE2)
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) (PHASE4)
- Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema (PHASE3)
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) (PHASE2)
- Patient Registry to Evaluate the Real-world Safety of Ruconest®
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant human C1 inhibitor CI brief — competitive landscape report
- recombinant human C1 inhibitor updates RSS · CI watch RSS
- Pharming Technologies B.V. portfolio CI
Frequently asked questions about recombinant human C1 inhibitor
What is recombinant human C1 inhibitor?
How does recombinant human C1 inhibitor work?
What is recombinant human C1 inhibitor used for?
Who makes recombinant human C1 inhibitor?
Is recombinant human C1 inhibitor also known as anything else?
What drug class is recombinant human C1 inhibitor in?
What development phase is recombinant human C1 inhibitor in?
What are the side effects of recombinant human C1 inhibitor?
What does recombinant human C1 inhibitor target?
Related
- Drug class: All Complement system regulator drugs
- Target: All drugs targeting C1 inhibitor
- Manufacturer: Pharming Technologies B.V. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Hereditary angioedema
- Also known as: "rhC1INH", Ruconest, conestat alfa, rhC1INH, Conestat alfa
- Compare: recombinant human C1 inhibitor vs similar drugs
- Pricing: recombinant human C1 inhibitor cost, discount & access